Best Peptide Stack for Fat Loss

Losing fat isn’t just about eating less. Hormones, metabolism, and cellular signaling all play a role — and when these systems slow down (as they do with age), willpower alone doesn’t cut it.

Peptide stacks for fat loss work by targeting the biological machinery behind fat storage and breakdown. Some boost growth hormone to improve body composition. Others act directly on fat cells or rev up mitochondrial function. The right combination depends on where your fat is, how your metabolism works, and what else you’re trying to accomplish. For a broader look at the field, see our guide to peptides for weight loss and peptide therapy basics.

Key Takeaways

• Tesamorelin is the only FDA-approved peptide specifically shown to reduce visceral fat (15–18% trunk fat reduction in trials)
• Combining a GH-releasing stack (CJC-1295 + Ipamorelin) with a metabolism-targeting peptide (MOTS-c or AOD-9604) covers more fat loss pathways
• GLP-1 peptides like semaglutide remain the most potent single-agent option, but stacking other peptides can address muscle preservation and metabolic health
• All fat loss peptide protocols work best alongside proper nutrition and exercise — they’re amplifiers, not replacements

Table of Contents

• How Peptides Target Fat Loss
• Stack 1: Tesamorelin + MOTS-c — Best for Visceral Fat
• Stack 2: CJC-1295 + Ipamorelin — Best for Body Recomposition
• Stack 3: AOD-9604 + CJC-1295 — Best for Targeted Fat Reduction
• Stack 4: Tesamorelin + CJC-1295 + Ipamorelin — Aggressive Protocol
• How Stacks Compare to GLP-1 Agonists
• Optimizing Your Fat Loss Stack
• Side Effects and Safety
• FAQ
• Sources

How Peptides Target Fat Loss

Fat loss peptides fall into three main categories based on their mechanism of action:

GH-releasing peptides (CJC-1295, Ipamorelin, Tesamorelin, Sermorelin) stimulate your pituitary gland to produce more growth hormone. Elevated GH increases lipolysis (fat breakdown), improves insulin sensitivity, and helps preserve lean muscle during caloric deficits [1]. This matters because muscle tissue is metabolically active — the more you keep, the more calories you burn at rest.

Direct fat-targeting peptides (AOD-9604) act on fat cells without going through the GH pathway. AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) that stimulates lipolysis and inhibits lipogenesis (fat creation) without affecting blood sugar or growth [2].

Metabolic peptides (MOTS-c) work at the mitochondrial level. MOTS-c activates AMPK — the same energy-sensing pathway triggered by exercise and fasting — to improve how your cells process fuel [3]. Think of it as making your cellular engines run more efficiently.

Understanding these categories helps you build stacks that hit fat from multiple angles rather than doubling up on the same pathway. For more on how peptides work, we have a dedicated explainer.

Stack 1: Tesamorelin + MOTS-c — Best for Visceral Fat

Evidence Rating: Strong

This is the strongest evidence-backed stack for visceral fat — the deep abdominal fat wrapped around your organs that’s linked to metabolic disease, insulin resistance, and cardiovascular risk.

The Research

Tesamorelin has the strongest clinical data of any fat-loss peptide. It’s FDA-approved (as Egrifta) for reducing visceral adipose tissue in HIV-associated lipodystrophy. In Phase III trials, patients saw a 15–18% reduction in trunk fat over 26 weeks, with improvements in triglycerides and cholesterol markers [4]. GH levels increase without the metabolic side effects of exogenous GH injections.

MOTS-c is newer but the preclinical data is compelling. A 2015 Cell Metabolism study showed that MOTS-c-treated mice had significantly reduced fat accumulation and improved insulin sensitivity, even on a high-fat diet [3]. It works through AMPK activation — the same pathway that metformin targets — but through a different mechanism.

Why They Stack Well

Tesamorelin handles the GH side: mobilizing stored fat and improving lipid profiles. MOTS-c handles the metabolic side: improving how your body processes the fuel it releases. One breaks fat down. The other makes sure your body actually uses it.

Protocol

• Tesamorelin: 2 mg subcutaneous daily (typically evening)
• MOTS-c: 5–10 mg subcutaneous, 3x per week
• Duration: 12–26 weeks with regular bloodwork
• Support: Caloric deficit of 300–500 calories, resistance training 3x/week

Best For

• Patients with elevated visceral fat (waist circumference > 40” men, > 35” women)
• Metabolic syndrome markers (high triglycerides, insulin resistance)
• Those who want fat loss without appetite suppression side effects

Stack 2: CJC-1295 + Ipamorelin — Best for Body Recomposition

Evidence Rating: Strong

If your goal isn’t just losing fat but simultaneously building muscle — body recomposition — this is the gold standard peptide stack. It’s also the most widely prescribed combination in anti-aging and performance clinics.

The Research

CJC-1295 produces sustained, dose-dependent GH increases of 2- to 10-fold that last 6+ days after a single injection. IGF-1 rises 1.5- to 3-fold and stays elevated for 9–11 days [5]. Ipamorelin adds acute GH pulses with a selectivity profile that doesn’t spike cortisol or prolactin [6].

The combined GH elevation drives several fat-loss mechanisms: increased lipolysis, improved fat oxidation during exercise, better insulin sensitivity, and preservation of lean muscle mass during caloric restriction.

For the full breakdown, see our CJC-1295 + Ipamorelin guide and ipamorelin benefits.

Protocol

• CJC-1295 (no DAC): 100–300 mcg subcutaneous
• Ipamorelin: 200–300 mcg subcutaneous
• Timing: 30 minutes before bed, empty stomach
• Duration: 8–12 weeks on, 4 weeks off
• Support: High protein intake (1g/lb bodyweight), resistance training

Best For

• Simultaneous fat loss and muscle growth
• Patients over 35 with declining natural GH
• Athletes wanting improved body composition
• Those who also want better sleep and energy

Stack 3: AOD-9604 + CJC-1295 — Best for Targeted Fat Reduction

Evidence Rating: Moderate

AOD-9604 takes a different approach than full GH-releasing peptides. As a fragment of growth hormone, it triggers fat breakdown without the broader hormonal effects — no impact on blood sugar, no growth stimulation, no IGF-1 elevation [2].

The Research

A randomized, double-blind, placebo-controlled trial in obese adults showed that daily oral AOD-9604 (1 mg) for 12 weeks produced greater weight loss than placebo — approximately 2.6 kg vs. 0.8 kg [7]. While these numbers aren’t dramatic on their own, the compound specifically targeted fat mass without affecting lean tissue.

Pairing AOD-9604 with CJC-1295 gives you direct fat cell activation (AOD) plus systemic GH elevation (CJC-1295) for broader metabolic support. CJC-1295 also helps preserve muscle, which AOD-9604 alone doesn’t address.

Protocol

• AOD-9604: 250–300 mcg subcutaneous daily (morning, fasted)
• CJC-1295 (no DAC): 100–300 mcg subcutaneous (evening)
• Duration: 8–12 weeks
• Support: Moderate caloric deficit, regular cardio

Best For

• Patients who want fat loss without significant hormonal changes
• Those sensitive to GH-related side effects (water retention, joint stiffness)
• Targeted reduction of subcutaneous fat

Stack 4: Tesamorelin + CJC-1295 + Ipamorelin — Aggressive Protocol

Evidence Rating: Moderate (components individually supported)

This triple stack maximizes GH output for patients with significant fat loss goals and physician oversight. It combines Tesamorelin’s FDA-backed visceral fat reduction with the CJC-1295/Ipamorelin recomposition engine.

Rationale

Tesamorelin is itself a GHRH analog, so stacking it with CJC-1295 provides redundancy in the GHRH pathway — but at different pharmacokinetic profiles. Adding Ipamorelin (ghrelin pathway) ensures you’re stimulating GH release through two distinct receptor systems.

This is not a beginner stack. The combined GH elevation is substantial and requires monitoring of IGF-1 levels, fasting glucose, and insulin sensitivity.

Protocol

• Tesamorelin: 2 mg subcutaneous daily
• CJC-1295 (no DAC): 100 mcg subcutaneous nightly (lower dose due to Tesamorelin)
• Ipamorelin: 200 mcg subcutaneous nightly
• Duration: 12–16 weeks with monthly bloodwork
• Support: Structured nutrition plan, resistance training 4x/week

Best For

• Patients with significant visceral fat and body composition goals
• Those under active physician supervision with regular lab monitoring
• Cases where single-stack approaches haven’t produced adequate results

How Stacks Compare to GLP-1 Agonists

The elephant in the room: semaglutide and tirzepatide produce more dramatic scale weight loss than any GH-based peptide stack. Clinical trials show 15–22% body weight reduction with tirzepatide over 72 weeks [8].

So why consider peptide stacks instead?

Muscle preservation. GLP-1 agonists cause significant lean mass loss — up to 40% of the weight lost can be muscle [9]. GH-releasing stacks actively preserve and build muscle during fat loss.

Side effect profile. GLP-1 side effects (nausea, vomiting, gastroparesis) are common and sometimes severe. GH-releasing peptide stacks have a milder side effect profile for most patients.

Metabolic health beyond weight. GH-releasing stacks improve sleep quality, bone density, skin quality, and energy levels — benefits GLP-1 agonists don’t provide.

Combination approach. Some clinicians prescribe a GLP-1 agonist alongside CJC-1295/Ipamorelin to get the appetite suppression and fat loss of the GLP-1 with the muscle preservation of the GH stack. This requires careful monitoring.

For more context, read our peptides for fat loss comparison guide.

Optimizing Your Fat Loss Stack

The peptides are only part of the equation. These factors determine whether your stack actually delivers results:

Nutrition timing. GH-releasing peptides work best on an empty stomach. Eating within 2 hours of injection blunts the GH response — insulin and GH are antagonistic. Fast for at least 2 hours before your evening dose.

Exercise. Resistance training 3–4x per week is non-negotiable. It amplifies GH’s anabolic effects and preserves lean mass. Add 2–3 sessions of moderate cardio for additional caloric expenditure.

Sleep. Your largest natural GH pulse happens during deep sleep. Poor sleep undermines the entire protocol. The CJC-1295/Ipamorelin stack typically improves sleep quality, but prioritize sleep hygiene regardless.

Caloric deficit. A moderate deficit (300–500 calories) works best. Aggressive restriction increases cortisol, which opposes GH and promotes fat storage — the opposite of what you want.

Bloodwork. Test IGF-1, fasting glucose, fasting insulin, and a lipid panel before starting and every 4–6 weeks during the protocol. This is how you and your doctor know the stack is working safely.

Learn more about timing in our when to take peptides guide.

Side Effects and Safety

Fat loss peptide stacks are generally well-tolerated, but stacking compounds increases the need for monitoring.

GH-releasing stacks (CJC-1295, Ipamorelin, Tesamorelin):

• Water retention (first 1–2 weeks, usually resolves)
• Injection site reactions
• Tingling in hands/feet
• Increased hunger (ipamorelin specifically)
• Joint stiffness at higher doses
• Potential impact on fasting blood glucose

AOD-9604:

• Mild injection site discomfort
• Headache (uncommon)
• Generally well-tolerated given its limited hormonal impact

MOTS-c:

• Limited human safety data — this is the honest caveat
• No significant adverse events reported in available studies
• Possible mild GI discomfort

Read our comprehensive peptide side effects guide and are peptides safe overview for the full picture.

Proper injection technique and peptide reconstitution are baseline requirements. Contaminated vials or incorrect preparation create avoidable risks.

FAQ

What is the fastest-acting peptide stack for fat loss?▼

For visible results in the shortest timeframe, the CJC-1295 + Ipamorelin stack typically shows body composition changes within 4–6 weeks when combined with proper diet and exercise. Tesamorelin produces measurable visceral fat reduction within 8–12 weeks based on imaging studies. No peptide stack produces overnight results — if someone promises that, be skeptical.

Can I stack a fat loss peptide with semaglutide?▼

Yes, some clinicians combine GLP-1 agonists like semaglutide with GH-releasing peptides to offset the muscle loss associated with GLP-1 therapy. This is an off-label approach that requires physician oversight. See our semaglutide vs tirzepatide comparison for more context on GLP-1 options.

Do fat loss peptide stacks work without exercise?▼

They can produce some fat reduction without exercise, particularly Tesamorelin for visceral fat. But the results are significantly better with resistance training. Exercise amplifies the GH response, preserves muscle mass, and improves insulin sensitivity — all of which enhance what the peptides are doing.

How much fat can I lose with a peptide stack?▼

Results vary based on starting body composition, diet, exercise, and the specific stack. Clinical data for Tesamorelin shows 15–18% visceral fat reduction over 6 months. CJC-1295/Ipamorelin patients commonly report 5–15 lbs of fat loss over a 12-week cycle when combined with a structured program. These are amplifiers — the fundamentals still matter.

Are fat loss peptide stacks safe for women?▼

Yes. All the stacks listed here are used by women in clinical practice. Dosages may be adjusted based on body weight. GH-releasing peptides are particularly popular among women for body composition improvement without the masculinizing effects of androgenic compounds. See our guides on peptide therapy for women and peptides for men for gender-specific guidance.

Sources

1. Møller N, Jørgensen JO. “Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects.” Endocr Rev. 2009;30(2):152-177. PubMed

2. Heffernan M, et al. “The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.” Endocrinology. 2001;142(12):5182-5189. PubMed

3. Lee C, et al. “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” Cell Metab. 2015;21(3):443-454. PubMed

4. Falutz J, et al. “Metabolic effects of a growth hormone-releasing factor in patients with HIV.” N Engl J Med. 2007;357(23):2359-2370. PubMed

5. Teichman SL, et al. “Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295.” J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed

6. Raun K, et al. “Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol. 1998;139(5):552-561. PubMed

7. Thompson D, et al. “Lipolytic effects of an oral formulation of AOD9604 in obese human subjects.” Obes Res. 2004;12(8):1246. Abstract presented at NAASO Annual Meeting.

8. Jastreboff AM, et al. “Tirzepatide once weekly for the treatment of obesity.” N Engl J Med. 2022;387(3):205-216. PubMed

9. Wilding JPH, et al. “Once-weekly semaglutide in adults with overweight or obesity.” N Engl J Med. 2021;384(11):989-1002. PubMed